Related references
Note: Only part of the references are listed.GNAO1-related movement disorder with life-threatening exacerbations: movement phenomenology and response to DBS
Michaela Waak et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Treatable Inherited Rare Movement Disorders
H. A. Jinnah et al.
MOVEMENT DISORDERS (2018)
The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies
Jan Roth
PARKINSONISM & RELATED DISORDERS (2018)
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease
Emma M. Coppen et al.
DRUGS (2017)
Antipsychotic drugs in Huntington's disease
E. Unti et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)
Antipsychotic drugs in Huntington's disease
E. Unti et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)
Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study
Rita Miguel et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis
Maren Carbon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites
Dimitri E. Grigoriadis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Neuroacanthocytosis: A case with unusual clinical features & novel response to treatment
Connie K. Wu et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Randomized, Placebo-Controlled Trial of ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 3)
Wolfgang Oertel et al.
MOVEMENT DISORDERS (2017)
First deuterated drug approved
Charles Schmidt
NATURE BIOTECHNOLOGY (2017)
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
Daniel Ryskamp et al.
NEUROBIOLOGY OF DISEASE (2017)
Clinical manifestations of the anti-IgLON5 disease
Carles Gaig et al.
NEUROLOGY (2017)
Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia
Michael C. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients
Miryam Carecchio et al.
PARKINSONISM & RELATED DISORDERS (2017)
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea
Samuel Frank et al.
JAMA NEUROLOGY (2017)
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Marco Solmi et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial
Karen E. Anderson et al.
LANCET PSYCHIATRY (2017)
A case of severe movement disorder with GNAO1 mutation responsive to topiramate
Saori Sakamoto et al.
BRAIN & DEVELOPMENT (2017)
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia
Robert A. Hauser et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Huntington's Disease-Update on Treatments
Kara J. Wyant et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Benign Infantile Seizures and Paroxysmal Dyskinesia Caused by an SCN8A Mutation
Elena Gardella et al.
ANNALS OF NEUROLOGY (2016)
Recent advances in genetics of chorea
Niccolo E. Mencacci et al.
CURRENT OPINION IN NEUROLOGY (2016)
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia
Dhanya Vijayakumar et al.
DRUGS (2016)
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Dhanya Vijayakumar et al.
DRUGS (2016)
Pridopidine for the treatment of Huntington's disease
Kathleen M. Shannon
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Dopamine depleters in the treatment of hyperkinetic movement disorders
Joseph Jankovic
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Deep brain stimulation for the treatment of hyperkinetic movement disorders
Lazzaro di Biase et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease A Randomized Clinical Trial
Samuel Frank et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Progression of motor subtypes in Huntington's disease: a 6-year follow-up study
M. Jacobs et al.
JOURNAL OF NEUROLOGY (2016)
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease
Jose Luis Lopez-Sendon Moreno et al.
JOURNAL OF NEUROLOGY (2016)
Autoimmune choreas
Francisco Cardoso
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Phenotypic insights into ADCY5-associated disease
Florence C. F. Chang et al.
MOVEMENT DISORDERS (2016)
Deuterated drugs draw heavier backing
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2016)
Delineation of the movement disorders associated with FOXG1 mutations
Apostolos Papandreou et al.
NEUROLOGY (2016)
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea
Hyeyoung Park et al.
PARKINSONISM & RELATED DISORDERS (2016)
Deep brain stimulation for the treatment of hyperkinetic movement disorders
Lazzaro di Biase et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease
Ralf Reilmann
JAMA NEUROLOGY (2016)
Chorea in the older adult: a full blooded answer
A. J. Degnan et al.
JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH (2016)
Brain stimulation in Huntington's disease
Christian Johannes Hartmann et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2016)
Gluten chorea
Carlos Andrade et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2015)
Diagnosis and Treatment of Chorea Syndromes
Andreas Hermann et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2015)
Deep brain stimulation in Huntington's disease: Assessment of potential targets
Mayur Sharma et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
The Therapeutic Potential of Cannabinoids for Movement Disorders
Benzi Kluger et al.
MOVEMENT DISORDERS (2015)
Successful Combination of Pallidal and Thalamic Stimulation for Intractable Involuntary Movements in Patients with Neuroacanthocytosis
Naoki Nakano et al.
WORLD NEUROSURGERY (2015)
A prospective pilot trial for pallidal deep brain stimulation in Huntington's disease
Lars Wojtecki et al.
FRONTIERS IN NEUROLOGY (2015)
Increased Intracortical Inhibition in Hyperglycemic Hemichorea-Hemiballism
Jie-Yuan Li et al.
MOVEMENT DISORDERS (2015)
Changes in Motor Cortical Excitability in Patients With Sydenham's Chorea
Eman M. Khedr et al.
MOVEMENT DISORDERS (2015)
Lower limb monochorea from a globus pallidus infarct
Sanjay Pandey et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2014)
Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature
D. Gruber et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study
Victoria Gonzalez et al.
JOURNAL OF NEUROSURGERY (2014)
Chorea Associated With Huntington's Disease: To Treat or Not to Treat?
Joseph Jankovic et al.
MOVEMENT DISORDERS (2014)
Successful Treatment of Disabling Nonkinesigenic Dyskinesia with Deep Brain Stimulation of the Globus Pallidus Internus
Riaan van Coller et al.
STEREOTACTIC AND FUNCTIONAL NEUROSURGERY (2014)
Movement Disorder in Ataxia-Telangiectasia: Treatment With Amantadine Sulfate
Andreea Nissenkorn et al.
JOURNAL OF CHILD NEUROLOGY (2013)
Repetitive Transcranial Magnetic Stimulation Not Beneficial in Severe Choreiform Movements of Huntington Disease
Aniket Shukla et al.
JOURNAL OF ECT (2013)
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome
Jose Fidel Baizabal-Carvallo et al.
JOURNAL OF NEURAL TRANSMISSION (2013)
Movement disorders in cerebrovascular disease (vol 12, pg 597, 2013)
R. Mehanna et al.
LANCET NEUROLOGY (2013)
Analysis of CYP2D6 genotype and response to tetrabenazine
Raja Mehanna et al.
MOVEMENT DISORDERS (2013)
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline
Ralf Reilmann
MOVEMENT DISORDERS (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
Evidence-based guideline: Treatment of tardive syndromes Report of the Guideline Development Subcommittee of the American Academy of Neurology
Roongroj Bhidayasiri et al.
NEUROLOGY (2013)
Short and Long Term Outcome of Bilateral Pallidal Stimulation in Chorea-Acanthocytosis
Marie Miquel et al.
PLOS ONE (2013)
Recent advances in the management of choreas
Jean-Marc Burgunder
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2013)
Movement disorders in cerebrovascular disease
Raja Mehanna et al.
LANCET NEUROLOGY (2013)
Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature
Jack J. Chen et al.
CLINICAL THERAPEUTICS (2012)
Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene
Domitille Gras et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Deep brain stimulation in the treatment of chorea
Thomas C. Edwards et al.
MOVEMENT DISORDERS (2012)
Movement disorders in autoimmune diseases
Jose Fidel Baizabal-Carvallo et al.
MOVEMENT DISORDERS (2012)
Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease Report of the Guideline Development Subcommittee of the American Academy of Neurology
Melissa J. Armstrong et al.
NEUROLOGY (2012)
An evidence-based approach in the treatment of Huntington's disease
T. A. Mestre et al.
PARKINSONISM & RELATED DISORDERS (2012)
Postthalamic Stroke Dystonic Choreoathetosis Responsive to Tetrabenazine
Rocco Salvatore Calabrò et al.
ANNALS OF PHARMACOTHERAPY (2011)
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
Joseph Jankovic et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Justo Garcia de Yebenes et al.
LANCET NEUROLOGY (2011)
Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole
Maria Sierra Pena et al.
MOVEMENT DISORDERS (2011)
Dopamine and Glutamate in Huntington's Disease: A Balancing Act
Veronique M. Andre et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
Advances in the Pharmacological Management of Huntington's Disease
Samuel Frank et al.
DRUGS (2010)
Dramatic Response of Facial Stereotype/Tic to Tetrabenazine in the First Reported Cases of Neuroferritinopathy in the United States
William G. Ondo et al.
MOVEMENT DISORDERS (2010)
Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
Samuel Frank
BMC NEUROLOGY (2009)
Treatment of hyperkinetic movement disorders
Joseph Jankovic
LANCET NEUROLOGY (2009)
Treatment of the Symptoms of Huntington's Disease: Preliminary Results Comparing Aripiprazole and Tetrabenazine
Livia Brusa et al.
MOVEMENT DISORDERS (2009)
A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease
Adrienne Curtis et al.
MOVEMENT DISORDERS (2009)
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
Samuel Frank et al.
CLINICAL NEUROPHARMACOLOGY (2008)
Pallidal neuronal discharge in Huntington's disease: Support for selective loss of striatal cells originating the indirect pathway
Philip A. Starr et al.
EXPERIMENTAL NEUROLOGY (2008)
A Europe-Wide assessment of current medication choices in Huntington's disease
Josef Priller et al.
MOVEMENT DISORDERS (2008)
Riluzole in Huntington's disease: A 3-year, randomized controlled study
G. Bernhard Landwehrmeyer et al.
ANNALS OF NEUROLOGY (2007)
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
Christopher Kenney et al.
MOVEMENT DISORDERS (2007)
Circuits and circuit disorders of the basal ganglia
Mahlon R. DeLong et al.
ARCHIVES OF NEUROLOGY (2007)
Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Theresa A. Zesiewicz et al.
MOVEMENT DISORDERS (2006)
Randomized double-blind study with prednisone in Sydenham's chorea
JA Paz et al.
PEDIATRIC NEUROLOGY (2006)
Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series
C Saft et al.
BMC NEUROLOGY (2006)
Tetrabenazine as antichorea therapy in Huntington disease - A randomized controlled trial
FJ Marshall et al.
NEUROLOGY (2006)
Efficacy of levetiracetam in Huntington disease
M de Tommaso et al.
CLINICAL NEUROPHARMACOLOGY (2005)
Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis
A Al-Asmi et al.
EPILEPSIA (2005)
Levetiracetarn-induced parkinsonism in a Huntington disease patient
TA Zesiewicz et al.
CLINICAL NEUROPHARMACOLOGY (2005)
A Randomized trial of amantadine in Huntington disease
P O'Suilleabhain et al.
ARCHIVES OF NEUROLOGY (2003)
IV amantadine improves chorea in Huntington's disease - An acute randomized, controlled study
C Lucetti et al.
NEUROLOGY (2003)
Share Paper
